Sign inJoin waitlistJoin the waitlist

Gary Doolittle

Professor, Medical Oncology · University of Kansas School of Medicine

Credentials: · · ·

History

University of Kansas School of Medicine
Present

Hematology and Medical Oncology
University of Kansas School of Medicine
1987–1990
University of Kansas School of Medicine
1984–1987
University of Kansas School of Medicine
1980–1984

Research

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
New England Journal of Medicine · 2023 · 739 citations
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Nature Medicine · 2020 · 97 citations
Providing Access to Oncology Care for Rural Patients via Telemedicine
Journal of Oncology Practice · 2006 · First of 2 authors · 78 citations

AA
Ace Allen
6 papers
Antoni Ribas
4 papers
KK
Kari Kendra
4 papers
Sapna Patel
4 papers
AI
Alexandra Ikeguchi
3 papers
DB
David Bodensteiner
3 papers
ES
Elad Sharon
3 papers
Gino In
3 papers
Joseph McGuirk
3 papers
KG
Kenneth Grossmann
3 papers
TT
Thach-Giao Truong
3 papers
Vernon Sondak
3 papers

Grants

The University of Kansas Cancer Center's- MCA Rural NCORP
National Cancer Institute · UG1
Contact PI · $13.2M · University of Kansas Medical Center
2019–2027

Clinical trials

Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma
Principal investigator · Completed · Phase 1
Gary Doolittle
2016–2021
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Site PI · Recruiting · Phase 3
Replimune, Inc.
2024–2031